Date: May 14, 2026 | Trigger: Q1 2026 earnings miss, GLP-1 transition margin compression
1. What Happened
Hims & Hers (HIMS) reported Q1 2026 on May 11 with a significant miss on both lines:
| Metric | Actual | Estimate | YoY |
|---|---|---|---|
| Revenue | $608.1M | $616.9M (miss) | +3.8% |
| EPS (GAAP) | -$0.40 | +$0.04 (miss) | vs +$0.20 |
| Gross Margin | 65% | — | vs 73% (800bps compression) |
| Adj. EBITDA | $44.3M | — | vs $91.1M (-51%) |
| Subscribers | 2.584M | — | +9% YoY |
| Rev/Subscriber | ~$80/mo | — | vs $85/mo |
Stock dropped 11.5% on May 12 to ~$24.14. The loss includes $33.5M in restructuring charges (GLP-1 transition), $17.6M fair value losses on liabilities, and $9.7M on equity securities.
2. Recent News & Sentiment (Last 7 Days)
- Novo Nordisk Partnership: HIMS now offers branded Ozempic (0.5/1/2mg) and Wegovy (injections + oral tablets) on-platform, ending the compounded semaglutide legal dispute. Compounded GLP-1s will no longer be advertised.
- Analyst downgrades: JPMorgan cut PT to $33 (from $35, maintains OW). BofA cut to $30 (from $32, Neutral). Jefferies lowered PT on guidance cut. Consensus is recalibrating.
- Bullish outliers: Needham raised PT to $35 (Novo partnership upside). Canaccord raised to $32 (Buy).
- Guidance raised: FY2026 revenue $2.8B-$3.0B (implies massive H2 acceleration from $608M/Q run rate), Adj. EBITDA $275M-$350M.
- Sentiment: Heavily negative short-term. CNBC headline: “plummets 13%.” Social media bearish.
3. Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | ~$5.5B |
| Price | $24.14 (May 14) |
| P/S (trailing) | ~2.3x |
| 52-Week Range | ~$15-$72 |
| Cash | ~$200M (est.) |
| Shares Outstanding | ~228M |
| FY2026 Rev Guide | $2.8B-$3.0B |
The FY guide implies $2.2B-$2.4B in remaining Q2-Q4 revenue ($730M-$800M/Q), a 20-32% acceleration from Q1’s $608M. This is aggressive and requires the Novo partnership to ramp fast.
4. Competitive Landscape / Sector Dynamics
- GLP-1 telehealth: HIMS is pivoting from high-margin compounded semaglutide to lower-margin branded Novo products. Ro Health, Found, and Calibrate compete. HIMS has scale advantage (2.6M subs) but the margin profile changes fundamentally.
- Novo dependency: HIMS is now a distribution channel for Novo Nordisk’s GLP-1s, not a differentiated compounding play. This reduces regulatory risk but compresses margins and makes HIMS dependent on Novo’s pricing and supply decisions.
- FDA compounding enforcement: The shift to branded GLP-1s eliminates the overhang from potential FDA crackdowns on compounders. This was the right strategic move, but the transition cost is real.
5. Risk Factors
- Margin trajectory: 800bps gross margin compression in one quarter is structural, not transitional. Branded pharma distribution margins are inherently lower than compounded products. Recovery to 73% is unlikely.
- Guidance credibility: FY revenue guide requires Q2-Q4 to average $730M+/Q (20%+ sequential growth). This depends on Novo partnership ramping faster than compounded revenue declines.
- Subscriber economics deteriorating: Rev/subscriber fell from $85 to $80. Branded GLP-1s may not reverse this if patients shift to lower-priced tiers or insurance-covered options.
- One-time charge skepticism: $33.5M “restructuring” and $27.3M in fair value losses are labeled non-recurring, but the GLP-1 transition is multi-quarter. More charges are possible.
- Options IV: Post-earnings IV is elevated, making puts expensive. Need to wait for IV crush before initiating.
6. Conclusion
Rating: BEARISH | Conviction: Medium (6/10)
The Q1 miss is not just one-time charges. The 800bps gross margin compression from 73% to 65% reflects a fundamental shift from high-margin compounding to lower-margin branded pharma distribution. Revenue per subscriber is declining. The FY guide requiring 20%+ sequential growth from Q2 onward is aggressive and unproven.
The Novo partnership is strategically correct but economically dilutive. HIMS traded away its margin moat (compounding) to eliminate regulatory risk. The market is right to reprice.
Put play assessment: Options are available (May 15/22/29 expirations + monthlies). However, post-earnings IV is elevated, making puts expensive now. A put spread (buy $24, sell $20, June expiry) could work if IV compresses over the next 1-2 weeks. Wait for IV to settle before entering. If the stock bounces to $26-27 on a relief rally, that’s the entry window for a bearish position.
Key watch: Q2 subscriber adds and rev/subscriber. If both decline sequentially, the bull thesis is broken. If HIMS can show 100K+ monthly weight loss subscriber adds (per management’s target), the narrative shifts.